Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07659678 · ClinicalTrials.gov registry record · Phase 2
CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma
A Phase 2 study, sponsored by Washington University School of Medicine.
- Not yet
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT07659678 is a Phase 2 study that has not yet begun recruiting, run by Washington University School of Medicine. The registered enrollment target is 90 participants.
The verdict
NCT07659678, a Phase 2 study, has not yet begun recruiting, sponsored by Washington University School of Medicine.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This is a prospective study to evaluate the sensitivity and specificity of Cu-64 DOTA-ECL1i PET/CT imaging to serve as a novel precision imaging tool for patients with head and neck squamous cell carcinoma (HNSCC).
Interventions
- DRUG 64Cu-DOTA-ECL1i
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-08-31 |
| Est. Completion | 2032-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07659678
The ClinicalTrials.gov registry entry for NCT07659678 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 64Cu-DOTA-ECL1i is the first listed.
NCT07659678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07659678 about?
NCT07659678 is a clinical study titled "CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma". This is a prospective study to evaluate the sensitivity and specificity of Cu-64 DOTA-ECL1i PET/CT imaging to serve as a novel precision imaging tool for patients with head and neck squamous cell carcinoma (HNSCC).
What is the current status of trial NCT07659678?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2026-08-31. Estimated completion is 2032-03-31.
What interventions are being tested in trial NCT07659678?
The interventions under investigation include: 64Cu-DOTA-ECL1i (DRUG).
Who is sponsoring clinical trial NCT07659678?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.